# A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve

Study · id `cardio:ct-nct05941455` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05941455](<https://clinicaltrials.gov/study/NCT05941455>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05941455

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 155 participants.

## Technical summary

Registry record NCT05941455. Allocation not applicable; no masking; primary purpose treatment. Start 2023-10-31 (anticipated); primary completion 2025-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 155 participants (planned count; ClinicalTrials.gov record NCT05941455, source copy `cardio:ctgov-nct05941455-2023-07-12`, retrieved 2026-10-26)
- Planned start: 2023-10-31 (anticipated) (ClinicalTrials.gov record NCT05941455, source copy `cardio:ctgov-nct05941455-2023-07-12`, retrieved 2026-10-26)
- Primary completion: 2025-10-31 (anticipated) (ClinicalTrials.gov record NCT05941455, source copy `cardio:ctgov-nct05941455-2023-07-12`, retrieved 2026-10-26)
- Completion: 2029-10-31 (anticipated) (ClinicalTrials.gov record NCT05941455, source copy `cardio:ctgov-nct05941455-2023-07-12`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT05941455, source copy `cardio:ctgov-nct05941455-2023-07-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05941455-2023-07-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve
- Acronym: METASAR
- Condition: Aortic Valve Disease
- Condition: Cardiovascular Diseases
- Intervention (Device): Venus-Neo Surgical Aortic Valve
- Lead sponsor: Jilin Venus Haoyue Medtech Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: afebefdbadd2318e33e1986b56f169484d15366e4245b198bf4a4f25f145b944
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
